AAAAAA
Results:
1-10
|
Results: 10
Authors:
Frankel, AE
Schuster, MW
Jurcic, JG
Citation: Ae. Frankel et al., Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia, BIODRUGS, 15(1), 2001, pp. 55-71
Authors:
Jurcic, JG
Citation: Jg. Jurcic, Antibody therapy for residual disease in acute myelogenous leukemia, CR R ONC H, 38(1), 2001, pp. 37-45
Authors:
Wang, ES
Maslak, P
Cathcart, K
Jurcic, JG
Citation: Es. Wang et al., Acute myeloid leukemia with t(5;18)(q35;q21), CANC GENET, 127(1), 2001, pp. 71-73
Authors:
Kolbert, KS
Hamacher, KA
Jurcic, JG
Scheinberg, DA
Larson, SM
Sgouros, G
Citation: Ks. Kolbert et al., Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia, J NUCL MED, 42(1), 2001, pp. 27-32
Authors:
Jurcic, JG
Nimer, SD
Scheinberg, DA
DeBlasio, T
Warrell, RP
Miller, WH
Citation: Jg. Jurcic et al., Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia, BLOOD, 98(9), 2001, pp. 2651-2656
Authors:
Jurcic, JG
Citation: Jg. Jurcic, Antibody therapy of acute myelogenous leukemia, CANC BIO R, 15(4), 2000, pp. 319-326
Authors:
Jurcic, JG
DeBlasio, T
Dumont, L
Yao, TJ
Scheinberg, DA
Citation: Jg. Jurcic et al., Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia, CLIN CANC R, 6(2), 2000, pp. 372-380
Authors:
Jurcic, JG
Cathcart, K
Pinilla-Ibarz, J
Scheinberg, DA
Citation: Jg. Jurcic et al., Advances in immunotherapy of hematologic malignancies: Cellular and humoral approaches, CURR OPIN H, 7(4), 2000, pp. 247-254
Authors:
Kossman, SE
Scheinberg, DA
Jurcic, JG
Jimenez, J
Caron, PC
Citation: Se. Kossman et al., A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia, CLIN CANC R, 5(10), 1999, pp. 2748-2755
Authors:
Sgouros, G
Ballangrud, AM
Jurcic, JG
McDevitt, MR
Humm, JL
Erdi, YE
Mehta, BM
Finn, RD
Larson, SM
Scheinberg, DA
Citation: G. Sgouros et al., Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients with leukemia, J NUCL MED, 40(11), 1999, pp. 1935-1946
Risultati:
1-10
|